Remove Definition Remove Licensing Remove Packaging
article thumbnail

Still working with Sitecore without Docker? Check Sifon, your new multitool in a Sitecore toolbelt

Perficient: Drug Development

Hey Sitecore professionals, if you have not heard about Sifon for Sitecore – you must definitely check this out. I spent a lot of time building and testing it and can say Sifon is a definite Swiss army knife for local Sitecore development in the right arms, so you’d really like to learn why. Just one click to it.

article thumbnail

Do You Have a Combination Product, and Is It Drug-led or Device-led? Early Regulatory Insights

The Premier Consulting Blog

Determining if you have a combination product The high-level definition of combination product seems straightforward: a product with at least two constituent parts, such as: Drug/biologic (e.g., metered-dose inhaler) However, the four-part definition in 21 CFR 3.2(e) The drug product is packaged and shipped as a solid powder.

article thumbnail

Article EMA Thank You New MHRA Windsor Framework documents guide post-Brexit flow of medicines for U.K., Great Britain, and the E.U.

Agency IQ

Definitions from the existing E.U. These features should not be included on outer packaging or immediate packaging, if there is no outer packaging. Last week, the MHRA provided a roadmap for upcoming labeling requirements, based on license type The Windsor Framework allows the MHRA to approve medicines for U.K.

article thumbnail

Q&A: The IND Journey Phase I – Navigating Success

Advarra

Q: What is the typical time period between the submission of the briefing package and the pre-IND meeting? A: The FDA’s guidance document indicates the briefing package is submitted four weeks before the meeting. Q: What is the definition of a drug? A: This is a complex topic and is best outlined in the FDA’s guidance document.

article thumbnail

Analysis Life Sciences Thank You FDA fiscal year in review: New drug approvals in the wake of the pandemic and legislative reforms

Agency IQ

All products are received in one of two forms: A New Drug Application (or NDA, for pharmaceuticals) or a Biologics License Application (BLA, for biologics). While the definition of NME has changed over the years, it can sometimes include a combination product consisting of at least one drug that has previously been approved.

FDA 52
article thumbnail

Analysis Life Sciences Thank You Halfway there: Novel drug approvals and their supportive clinical trials so far in 2024

Agency IQ

All products are received in one of two forms: A New Drug Application (or NDA, for pharmaceuticals) or a Biologics License Application (BLA, for biologics). While the definition of NME has changed over the years, it can sometimes include a combination product consisting of at least one drug that has previously been approved.

article thumbnail

Article FDA Thank You CDER’s latest novel drug approvals report shows how the pandemic is still affecting some drug approvals

Agency IQ

These windows depend on whether the new drug application (NDA) or biologics license application (BLA) is a new molecular entity, and if the application has received standard review (10 months, plus 2 months of administrative time) or priority review (6 months, plus 2 months of administrative time).

FDA 40